99 related articles for article (PubMed ID: 26612030)
1. Theoretical studies of energetics and binding isotope effects of binding a triazole-based inhibitor to HIV-1 reverse transcriptase.
Krzemińska A; Świderek KP; Paneth P
Phys Chem Chem Phys; 2016 Jan; 18(1):310-7. PubMed ID: 26612030
[TBL] [Abstract][Full Text] [Related]
2. Oxygen binding isotope effects of triazole-based HIV-1 reverse transcriptase inhibitors indicate the actual binding site.
Krzemińska A; Frączek T; Paneth P
Arch Biochem Biophys; 2017 Dec; 635():87-95. PubMed ID: 29111294
[TBL] [Abstract][Full Text] [Related]
3. Binding isotope effects as a tool for distinguishing hydrophobic and hydrophilic binding sites of HIV-1 RT.
Krzemińska A; Paneth P; Moliner V; Świderek K
J Phys Chem B; 2015 Jan; 119(3):917-27. PubMed ID: 25132465
[TBL] [Abstract][Full Text] [Related]
4. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
Kirschberg TA; Balakrishnan M; Huang W; Hluhanich R; Kutty N; Liclican AC; McColl DJ; Squires NH; Lansdon EB
Bioorg Med Chem Lett; 2008 Feb; 18(3):1131-4. PubMed ID: 18083512
[TBL] [Abstract][Full Text] [Related]
5. Searching for novel scaffold of triazole non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Frączek T; Paneth A; Kamiński R; Krakowiak A; Paneth P
J Enzyme Inhib Med Chem; 2016; 31(3):481-9. PubMed ID: 25942362
[TBL] [Abstract][Full Text] [Related]
6. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
Rodríguez-Barrios F; Gago F
J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
[TBL] [Abstract][Full Text] [Related]
7. Docking and quantitative structure-activity relationship studies for the bisphenylbenzimidazole family of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Lagos CF; Caballero J; Gonzalez-Nilo FD; David Pessoa-Mahana C; Perez-Acle T
Chem Biol Drug Des; 2008 Nov; 72(5):360-9. PubMed ID: 19012572
[TBL] [Abstract][Full Text] [Related]
8. The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations.
Rodríguez-Barrios F; Balzarini J; Gago F
J Am Chem Soc; 2005 May; 127(20):7570-8. PubMed ID: 15898808
[TBL] [Abstract][Full Text] [Related]
9. Theoretical studies of HIV-1 reverse transcriptase inhibition.
Świderek K; Martí S; Moliner V
Phys Chem Chem Phys; 2012 Sep; 14(36):12614-24. PubMed ID: 22820901
[TBL] [Abstract][Full Text] [Related]
10. Additional level of information about complex interaction between non-nucleoside inhibitor and HIV-1 reverse transcriptase using biosensor-based thermodynamic analysis.
Geitmann M; Danielson UH
Bioorg Med Chem; 2007 Dec; 15(23):7344-54. PubMed ID: 17870544
[TBL] [Abstract][Full Text] [Related]
11. Application of the Huisgen cycloaddition and 'click' reaction toward various 1,2,3-triazoles as HIV non-nucleoside reverse transcriptase inhibitors.
Pribut N; Veale CG; Basson AE; van Otterlo WA; Pelly SC
Bioorg Med Chem Lett; 2016 Aug; 26(15):3700-4. PubMed ID: 27287366
[TBL] [Abstract][Full Text] [Related]
12. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
13. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase.
Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM
Biochem Pharmacol; 2000 Nov; 60(9):1251-65. PubMed ID: 11008119
[TBL] [Abstract][Full Text] [Related]
14. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Madura JD
Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
[TBL] [Abstract][Full Text] [Related]
15. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
[TBL] [Abstract][Full Text] [Related]
16. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
Zhou Z; Madura JD
Proteins; 2004 Nov; 57(3):493-503. PubMed ID: 15382241
[TBL] [Abstract][Full Text] [Related]
17. Thermodynamics of HIV-1 reverse transcriptase in action elucidates the mechanism of action of non-nucleoside inhibitors.
Bec G; Meyer B; Gerard MA; Steger J; Fauster K; Wolff P; Burnouf D; Micura R; Dumas P; Ennifar E
J Am Chem Soc; 2013 Jul; 135(26):9743-52. PubMed ID: 23742167
[TBL] [Abstract][Full Text] [Related]
18. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, biological evaluation and molecular modeling studies of N-aryl-2-arylthioacetamides as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Xiaohe Z; Yu Q; Hong Y; Xiuqing S; Rugang Z
Chem Biol Drug Des; 2010 Oct; 76(4):330-9. PubMed ID: 20731670
[TBL] [Abstract][Full Text] [Related]
20. Assessing molecular docking tools for relative biological activity prediction: a case study of triazole HIV-1 NNRTIs.
Frączek T; Siwek A; Paneth P
J Chem Inf Model; 2013 Dec; 53(12):3326-42. PubMed ID: 24266618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
